AstraZeneca reports follow up results from FLAURA2 Phase 3 trial

Results from the FLAURA2 Phase 3 trial showed AstraZeneca’s Tagrisso with the addition of chemotherapy provided a clinically meaningful and consistent benefit in subsequent outcomes after disease progression in patients with locally advanced or metastatic epidermal growth factor receptor-mutated non-small cell lung cancer, or NSCLC, the company announced. Tagrisso with the addition of chemotherapy also demonstrated a favorable trend toward overall survival, or OS, improvement at two years of follow up. These results were presented at the 2024 European Lung Cancer Congress, or ELCC, in Prague, Czech Republic. “This follows primary endpoint data presented at the International Association for the Study of Lung Cancer 2023 World Conference on Lung Cancer and published in The New England Journal of Medicine, which showed Tagrisso with the addition of chemotherapy demonstrated a statistically significant and clinically meaningful improvement in progression-free survival – PFS. In February 2024, Tagrisso with the addition of chemotherapy was approved in the US following a Priority Review by the Food and Drug Administration based on these results,” the company noted.